Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 21, 2026, 7:18 PM EDT
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 21 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced May 21, 2026, 7:18 PM EDT
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Month and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced May 21, 2026, 7:18 PM EDT
Conditions
ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma, MET Fusion Gene Positive, NRAS wt Allele, NTRK1 Fusion Positive, NTRK2 Fusion Positive, NTRK3 Fusion Positive, RET Fusion Positive, ROS1 Fusion Positive, Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Interventions
Capmatinib, Ceritinib, Entrectinib, Laboratory Biomarker Analysis, Regorafenib
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced May 21, 2026, 7:18 PM EDT
Conditions
Solid Tumor
Interventions
ONO-7579
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lake Success, New York • New York, New York • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced May 21, 2026, 7:18 PM EDT
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced May 21, 2026, 7:18 PM EDT